Vor Bio announced on July 1, 2025, that its Board of Directors granted Jean-Paul Kress, the company’s newly appointed Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio’s common stock. This grant was made in connection with the commencement of his employment.
The stock option has a ten-year term and an exercise price of $0.89 per share, which was equal to the closing price of Vor Bio’s common stock on June 26, 2025. This inducement award is a standard practice to attract and retain top executive talent.
The option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the subsequent 36 months, contingent on Dr. Kress’s continued employment with Vor Bio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.